April 2025 ACIP Meeting Update: Influenza, COVID-19, HPV, RSV and Other Immunizations

Abstract

The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention, normally meets 3 times per year to develop US vaccine recommendations for use. The ACIP Work Groups conduct an in-depth review of the available scientific information regarding specific US Food and Drug Administration (FDA)–licensed vaccines or important vaccines in advanced stages of clinical development that are under consideration for FDA licensure and then present the information and their recommendation to the ACIP for a vote. If a recommendation receives a majority vote, it moves to the Centers for Disease Control and Prevention (CDC) Director for approval and, if approved, it is published in the CDC Morbidity and Mortality Weekly Report. At that point, the ACIP recommendation represents the official CDC recommendation for US immunizations. The ACIP met April 16–17, 2025, to discuss influenza vaccines, chikungunya vaccines, COVID-19 vaccines, respiratory syncytial virus (RSV) immunizations, meningococcal vaccines, Human Papillomavirus (HPV) vaccines, Mpox vaccines, and cytomegalovirus vaccines. This update summarizes the proceedings of these meetings, with an emphasis on topics that are most relevant to the pediatric population. Major updates for pediatric clinicians include information regarding HPV and meningococcal vaccination considerations and updates regarding RSV immunization in infants, which will likely be voted on during upcoming ACIP meetings.